---
schema_version: "secwatch.filing_event.v1"
accession: "0001701478-25-000051"
form_type: "8-K"
ticker: "AZTR"
cik: "0001701478"
company_name: "Azitra, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:19:41.011148+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Azitra Q3 net loss widens to $2.8M; cash $1.4M; first patient dosed in ATR-04 Ph1/2 trial

## Summary
- Net loss of $2.8M for Q3 2025, compared to $1.0M in Q3 2024.
- Cash and equivalents $1.4M as of Sept 30, 2025; raised $2.8M gross via equity line from Alumni Capital.
- Dosed first patient in Phase 1/2 trial for ATR-04 targeting EGFRi-associated rash; FDA Fast Track granted.
- Presented positive preclinical data for ATR-01 (ichthyosis vulgaris) at BIO-Europe.
- R&D expenses $1.2M (up from $1.0M), G&A $1.6M (down from $1.9M) YoY.

## SEC filing metadata
- accession: 0001701478-25-000051
- form_type: 8-K
- ticker: AZTR
- cik: 0001701478
- company_name: Azitra, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701478/000170147825000051/0001701478-25-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701478/000170147825000051/aztr-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701478-25-000051
- JSON: https://secwatch.observer/filing/0001701478-25-000051.json
- Plain text: https://secwatch.observer/filing/0001701478-25-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.